MoonLake Immunotherapeutics

MLTX - CIK 0001821586

Market cap$1.28 B

Rank#2452

SEC filings296

MoonLake Immunotherapeutics trades as MLTX and has a market capitalization of $1.28 B, making it the #2452 largest US-listed company by market value. This page tracks MoonLake Immunotherapeutics through 296 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Net income (latest FY)-$227.32MFY 2025

Operating cash flow (latest FY)-$196.01MFY 2025

Total assets (latest FY)$424.43MFY 2025

Financial performance

MLTX annual net incomeView details

MLTX operating cash flowView details

Key statistics

Market cap: $1.28 B
Share price (derived)market cap / shares outstanding: $17.41
EPS (diluted)FY 2025: $-3.53
Shares outstandingas of 2026-05-01: 0.07B
Total equityas of 2026-03-31: $254.02M
Return on equity: -89.5%
Long-term debtas of 2026-03-31: $99.02M
Cash & equivalentsas of 2026-03-31: $298.49M

Latest filings

Filing	Type	Filed
SCHEDULE 13G/A	-	2026-05-15
Insider trade	4	2026-05-13
Quarterly report	10-Q	2026-05-11
Major company event	8-K	2026-05-11
Annual report to shareholders	ARS	2026-04-21
Proxy materials	DEFA14A	2026-04-21
Proxy statement	DEF 14A	2026-04-21
Insider trade	4	2026-04-16

Browse the full filing history (296 filings)

Recent press releases

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results2026-05-10
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results | MoonLake Immunotherapeutics
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting2026-03-28
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting | MoonLake Immunotherapeutics
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results2026-02-22
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results | MoonLake Immunotherapeutics
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day2026-02-02
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day | MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

Similar companies

The largest companies sharing MoonLake Immunotherapeutics's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T MLTX vs LLY

JNJJohnson & Johnson$573.98 B MLTX vs JNJ

ABBVAbbVie Inc.$399.47 B MLTX vs ABBV

MRKMerck & Co., Inc.$293.16 B MLTX vs MRK

AZNAstraZeneca PLC$286.27 B MLTX vs AZN

Frequently asked questions

What is MoonLake Immunotherapeutics's market cap?

MoonLake Immunotherapeutics (MLTX) has a market capitalization of $1.28 B as of 2026-06-10, ranking #2452 among US-listed companies.

Is MoonLake Immunotherapeutics profitable?

In its latest fiscal year MoonLake Immunotherapeutics reported a net loss of $227.32M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.